NEW YORK, Dec. 02, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Impax Laboratories, Inc. securities (NASDAQ:IPXL) from February 25, 2014 through November 3, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Impax investors under the federal securities laws.
To join the Impax class action, go to http://www.rosenlegal.com/cases-981.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Impax was engaging and/or had engaged in conduct that would cause the antitrust division of the U.S. Department of Justice (“DOJ”) and the Connecticut Attorney General to conduct extensive investigations of possible collusion of generic drug pricing; (2) the DOJ investigation and the underlying conduct was likely to result in criminal charges against Impax, and possibly its officers and directors, for collusion of generic drug pricing; (3) Impax lacked effective internal controls over financial reporting; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-981.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Britain Courts Anthropic Amid US Defense Department Dispute
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Apple Turns 50: From Garage Startup to AI Crossroads
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 



